Biocon Ltd. News and Updates

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.

Load latest

Biocon Ltd.

23 Apr 2025

421.60

0.15%

Biocon Board Approves Plan To Raise Up To Rs 4,500 Crore

NDTV Profit

Biocon's board also approved the increasing of the company's authorised share capital from Rs 625 crore to Rs 700 crore.

Axis Direct increased Buy price target of Biocon Ltd. to 450.0 on 13 Nov, 2025.

Biocon Ltd.

15 Apr 2025

421.60

0.15%

Biocon subsidiary secures permission to launch biosimilar Yesafili in US

Business Standard

This agreement enables the company to launch in the US in the second half of calendar year 2026 or earlier in certain circumstances

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

11 Apr 2025

421.60

0.15%

Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

livemint

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Axis Direct increased Buy price target of Biocon Ltd. to 450.0 on 13 Nov, 2025.

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

Business Standard | 11 Apr 2025 1 more

Biocon Ltd.

04 Apr 2025

421.60

0.15%

Biocon Board Approves Rs 600 Crore Fundraising Through Private Placement of Commercial Papers

NDTV Profit

It, however, did not disclose reasons for raising the capital.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

02 Apr 2025

421.60

0.15%

Peter Bains steps down as CEO of Biocon, to serve as Syngene's MD & CFO

Business Standard

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

Biocon Ltd. has gained 10.32% in the last 1 Week

Biocon Ltd.

28 Mar 2025

421.60

0.15%

'Hang your head in shame': Kiran Mazumdar-Shaw calls out Bengaluru's crumbling civic state

Business Today

Highlighting the sad state of affairs in the Silicon Valley of India, Biocon chief Kiran Mazumdar-Shaw compared the city's streets to those in Ecuador and called out the poor state of urban planning.

Biocon Ltd. has gained 10.32% in the last 1 Week

Biocon Ltd.

24 Mar 2025

421.60

0.15%

Biocon gains 2% on US FDA nod for ANDA Norepinephrine Bitartrate Injection

Business Standard

The company's subsidiary has received approval from the US Food and Drug Administration (US FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial

Biocon Ltd. is trading above all available SMAs

Biocon subsidiary secures FDA approval for critical blood pressure medication

Business Line | 24 Mar 2025

Biocon Ltd.

05 Mar 2025

421.60

0.15%

Here's why Biocon share price popped 3% in trade on March 5; details here

Business Standard

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA

Biocon Ltd. has gained 18.38% in the last 1 Month

Biocon shares up 3% after US FDA nod for key cancer drugs

Economic Times | 05 Mar 2025 1 more

Biocon Ltd.

28 Feb 2025

421.60

0.15%

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Business Standard

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

Biocon Ltd. has gained 10.32% in the last 1 Week

Biocon Launches Diabetes, Obesity Management Drug In UK

NDTV Profit | 28 Feb 2025

Biocon Ltd.

25 Feb 2025

421.60

0.15%

Biocon share price in focus after arm launches product in US for autoimmune diseases

livemint

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved for multiple conditions, this product aims to improve patient access to affordable treatments, marking Biocon's first US product launch as a global biosimilars organisation.

Biocon Ltd. has gained 25.55% in the last 1 Year

Is Biocon Ltd. worth buying?

730 Votes:

Buy 75.07%

Sell 16.3%

Hold 8.63%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf

New 52W High today

Biocon Ltd. News and Updates

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.